OCULAR THERAPEUTIX, INC

OCULSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1393434

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$58.4M	$51.5M	$43.5M	$17.4M	$4.2M
Cost of Goods and Services Sold	$5.3M	$4.5M	$4.4M	$2.1M	$2.3M
Research and Development Expense	$61.1M	$53.5M	$50.1M	$28.7M	$41.1M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$82.4M	-$78.7M	-$78.0M	-$62.8M	-$85.8M
Interest Expense	—	—	$6.7M	$6.8M	$6.1M
Nonoperating Income (Expense)	$1.6M	$7.6M	$71.5M	-$92.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$457.9M	$252.1M	$149.3M	$204.9M	$261.9M
Assets, Current	$441.0M	$232.2M	$129.6M	$191.3M	$246.2M
Cash and Cash Equivalents, at Carrying Value	$195.8M	$102.3M	$164.2M	$228.1M	$54.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$32.4M	$26.2M	$21.3M	$21.1M	$12.3M
Inventory, Net	$3.0M	$2.3M	$2.0M	$1.3M	$1.2M
Liabilities	$142.6M	$160.9M	$113.9M	$116.9M	$185.8M
Liabilities, Current	$41.4M	$34.9M	$31.4M	$26.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$70.2M	-$59.6M	-$65.5M	-$53.6M	-$77.6M
Net Cash Provided by (Used in) Investing Activities	-$6.1M	-$3.7M	-$1.2M	-$841.0K	-$2.2M
Net Cash Provided by (Used in) Financing Activities	$169.8M	$1.5M	$2.9M	$228.0M	$75.3M
Payments to Acquire Property, Plant, and Equipment	$6.1M	$3.7M	$1.2M	$841.0K	$2.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)